Mineralys Therapeutics, Inc. Common Stock MLYS
i
Market datapartial · fetched 2026-11-12T02:23:32.094Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T23:13:59.800726661Z
FundamentalsAlpha Vantage · unavailable
Mineralys Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | 22.43 | 292.4% | 47.7% | |||
| 35Δ | 20.27 | 261.0% | 35.0% | 15.26 | 107.0% | 9.1% |
| 40Δ | 17.34 | 143.7% | 14.6% | 15.71 | 117.5% | 8.5% |
| 45Δ | 16.87 | 143.4% | 12.9% | 16.17 | 128.0% | 7.9% |
| 50Δ | 16.40 | 143.2% | 11.2% | 16.62 | 138.5% | 7.3% |
| 55Δ | 15.93 | 143.0% | 9.5% | 17.07 | 149.0% | 6.7% |
| 60Δ | 15.47 | 142.7% | 7.8% | 17.54 | 159.1% | 6.1% |
| 65Δ | 15.00 | 142.5% | 6.1% | 18.40 | 160.3% | 5.2% |
| 70Δ | 14.35 | 153.1% | 5.2% | 19.27 | 161.6% | 4.4% |
| 75Δ | 13.69 | 163.7% | 4.4% | 20.14 | 162.8% | 3.5% |
| 80Δ | 13.04 | 174.3% | 3.5% | 21.00 | 164.0% | 2.6% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 22.43
- IV
- 292.4%
- B/E move
- 47.7%
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 20.27
- IV
- 261.0%
- B/E move
- 35.0%
- Pseudo strike
- 15.26
- IV
- 107.0%
- B/E move
- 9.1%
40Δ
- Pseudo strike
- 17.34
- IV
- 143.7%
- B/E move
- 14.6%
- Pseudo strike
- 15.71
- IV
- 117.5%
- B/E move
- 8.5%
45Δ
- Pseudo strike
- 16.87
- IV
- 143.4%
- B/E move
- 12.9%
- Pseudo strike
- 16.17
- IV
- 128.0%
- B/E move
- 7.9%
50Δ
- Pseudo strike
- 16.40
- IV
- 143.2%
- B/E move
- 11.2%
- Pseudo strike
- 16.62
- IV
- 138.5%
- B/E move
- 7.3%
55Δ
- Pseudo strike
- 15.93
- IV
- 143.0%
- B/E move
- 9.5%
- Pseudo strike
- 17.07
- IV
- 149.0%
- B/E move
- 6.7%
60Δ
- Pseudo strike
- 15.47
- IV
- 142.7%
- B/E move
- 7.8%
- Pseudo strike
- 17.54
- IV
- 159.1%
- B/E move
- 6.1%
65Δ
- Pseudo strike
- 15.00
- IV
- 142.5%
- B/E move
- 6.1%
- Pseudo strike
- 18.40
- IV
- 160.3%
- B/E move
- 5.2%
70Δ
- Pseudo strike
- 14.35
- IV
- 153.1%
- B/E move
- 5.2%
- Pseudo strike
- 19.27
- IV
- 161.6%
- B/E move
- 4.4%
75Δ
- Pseudo strike
- 13.69
- IV
- 163.7%
- B/E move
- 4.4%
- Pseudo strike
- 20.14
- IV
- 162.8%
- B/E move
- 3.5%
80Δ
- Pseudo strike
- 13.04
- IV
- 174.3%
- B/E move
- 3.5%
- Pseudo strike
- 21.00
- IV
- 164.0%
- B/E move
- 2.6%
Options history
Table
| Date | IV (%) |
|---|---|
| 88.16% | |
| 85.33% | |
| 84.49% | |
| 84.01% | |
| 93.06% | |
| 91.06% | |
| 100.55% | |
| 105.47% | |
| 90.83% | |
| 96.99% |
Biotechnology
MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung diseases in the United…
More →MPLT
MapLight Therapeutics, Inc. is an innovative biotechnology company that is dedicated to developing groundbreaking therapies for complex neurological and psychiatric disorders.…
More →MRNA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases,…
More →MRVI
Maravai LifeSciences Holdings, Inc., a life sciences company, offers products to enable the development of drug therapies, diagnostics, novel vaccines, and to support human…
More →NAMS
Description unavailable
More →NAUT
Nautilus Biotechnology, Inc., a development-stage life sciences company, is dedicated to creating platform technology to quantify and unlock proteome complexity. The company is…
More →